NCEL NewcelX Ltd.
Price Chart
Executive Summary
NewcelX Ltd. (NCEL) announced a $1.35 million private placement financing at $2.75 per share, representing a 30% premium to its prior closing price. The offering includes common shares (or pre-funded warrants) and five-year warrants to purchase up to 687,270 additional shares at $3.025 per share. The company plans to use the proceeds, combined with a $25 million equity line, to advance its lead Type 1 Diabetes program, NCEL-101, and for general corporate purposes.
Actionable Insight
The 30% premium pricing is a strong positive signal, indicating robust investor demand and confidence in the company's strategy, especially in a challenging biotech funding environment. Traders should monitor the closing of the offering around April 15, 2026, and watch for any updates on the NCEL-101 program's advancement, which could be a key future catalyst. The significant warrant overhang represents potential future dilution.
Key Facts
- NewcelX raised $1.35 million in a private placement at $2.75 per share.
- The offering price represents a 30% premium to the stock's closing price on March 31, 2026.
- The financing includes warrants to purchase up to 687,270 additional shares at $3.025 per share, potentially adding $2.1 million in future gross proceeds.
- Proceeds will be used to advance the NCEL-101 program for Type 1 Diabetes and for general corporate purposes.
- The offering includes participation from existing shareholders, signaling continued investor confidence.
Financial Impact
The immediate gross proceeds are $1,350,000. Full cash exercise of the warrants could generate an additional $2,088,991.50 (687,270 shares * $3.025).
Risk Factors
- The offering is subject to customary closing conditions and may not close.
- Full exercise of the warrants would result in significant share dilution.
- The company operates in the high-risk biotech sector, where clinical trial failures are common.
Market Snapshot
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-038619 |
| Document: ea028455201ex10-2.htm | 0001213900-26-038619 |
| Document: ea028455201ex10-3.htm | 0001213900-26-038619 |
| Document: ea0284552-6k_newcelx.htm | 0001213900-26-038619 |
| Document: ea028455201ex99-1.htm | 0001213900-26-038619 |
| Document: 0001213900-26-038619-index-headers.html | 0001213900-26-038619 |
| Document: 0001213900-26-038619-index.html | 0001213900-26-038619 |
| Document: 0001213900-26-038619.txt | 0001213900-26-038619 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
6-K
| $3.07 awaiting T+5 | awaiting T+5 | — | $3.24 (+5.54%) |
|
May 27, 2026
13d ago
|
Press Release
| $3.45 $3.32 | ▼ −3.77% | ▼ −4.98% | $3.24 (−6.09%) |
|
May 18, 2026
23d ago
|
EFFECT
| $3.11 $3.15 | ▼ −1.29% | ▲ +0.33% | $3.24 (−4.18%) |
|
May 7, 2026
4w ago
|
EFFECT
| $3.24 $3.24 | · 0.00% | ▼ −1.50% | $3.24 (+0.00%) |
|
Apr 30, 2026
5w ago
|
Press Release
| $4.41 $3.32 | ▲ +24.72% | ▲ +26.44% | $3.24 (+26.53%) |
|
Apr 20, 2026
7w ago
|
6-K
| $2.83 $3.87 | ▲ +36.75% | ▲ +35.84% | $3.24 (+14.49%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $2.83 $3.87 | ▲ +36.75% | ▲ +35.84% | $3.24 (+14.49%) |
|
Apr 1, 2026
9w ago
|
6-K
| $2.26 $2.49 | ▲ +10.42% | ▲ +6.80% | $3.24 (+43.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access